298 related articles for article (PubMed ID: 28459498)
21. Tumor-induced osteomalacia treated with T12 tumor resection.
Mancini AJ; Sabet A; Nielsen GP; Parker JA; Schwab JH; Ward A; Wu JS; Malabanan AO
Endocrinol Diabetes Metab Case Rep; 2022 Dec; 2022():. PubMed ID: 36511458
[TBL] [Abstract][Full Text] [Related]
22. Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance.
Hidaka N; Koga M; Kimura S; Hoshino Y; Kato H; Kinoshita Y; Makita N; Nangaku M; Horiguchi K; Furukawa Y; Ohnaka K; Inagaki K; Nakagawa A; Suzuki A; Takeuchi Y; Fukumoto S; Nakatani F; Ito N
J Bone Miner Res; 2022 Aug; 37(8):1479-1488. PubMed ID: 35690913
[TBL] [Abstract][Full Text] [Related]
23. Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.
Hartley IR; Roszko KL; Li X; Pozo K; Streit J; Del Rivero J; Magone MT; Smith MR; Vold R; Dambkowski CL; Collins MT; Gafni RI
JBMR Plus; 2022 Aug; 6(8):e10661. PubMed ID: 35991529
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Induced Osteomalacia.
Florenzano P; Hartley IR; Jimenez M; Roszko K; Gafni RI; Collins MT
Calcif Tissue Int; 2021 Jan; 108(1):128-142. PubMed ID: 32504138
[TBL] [Abstract][Full Text] [Related]
25. Long-term use of burosumab for the treatment of tumor-induced osteomalacia.
Crotti C; Zucchi F; Alfieri C; Caporali R; Varenna M
Osteoporos Int; 2023 Jan; 34(1):201-206. PubMed ID: 35925260
[TBL] [Abstract][Full Text] [Related]
26. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
27. Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Abramson M; Glezerman IG; Srinivasan M; Ross R; Flombaum C; Gutgarts V
Clin Nephrol; 2021 Feb; 95(2):104-111. PubMed ID: 33191899
[TBL] [Abstract][Full Text] [Related]
28. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.
Horng JC; Van Eperen E; Tutton S; Singh R; Shaker JL; Wooldridge AN
Osteoporos Int; 2021 Sep; 32(9):1895-1898. PubMed ID: 33655402
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
30. Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report.
Oe Y; Kameda H; Nomoto H; Sakamoto K; Soyama T; Cho KY; Nakamura A; Iwasaki K; Abo D; Kudo K; Miyoshi H; Atsumi T
Medicine (Baltimore); 2021 Nov; 100(46):e27895. PubMed ID: 34797338
[TBL] [Abstract][Full Text] [Related]
31. Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia.
Abate V; Vergatti A; De Filippo G; Damiano V; Menale C; D'Elia L; Rendina D
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1006-e1011. PubMed ID: 38006315
[TBL] [Abstract][Full Text] [Related]
32. Burosumab for the Treatment of Tumor-Induced Osteomalacia.
Jan de Beur SM; Miller PD; Weber TJ; Peacock M; Insogna K; Kumar R; Rauch F; Luca D; Cimms T; Roberts MS; San Martin J; Carpenter TO
J Bone Miner Res; 2021 Apr; 36(4):627-635. PubMed ID: 33338281
[TBL] [Abstract][Full Text] [Related]
33. Tumor induced osteomalacia: A single center experience on 17 patients.
Crotti C; Bartoli F; Coletto LA; Manara M; Marini E; Daolio PA; Parafioriti A; Armiraglio E; Zucchi F; Sinigaglia L; Caporali R; Varenna M
Bone; 2021 Nov; 152():116077. PubMed ID: 34175499
[TBL] [Abstract][Full Text] [Related]
34. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
[TBL] [Abstract][Full Text] [Related]
35. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
36. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.
Bai X; Miao D; Li J; Goltzman D; Karaplis AC
Endocrinology; 2004 Nov; 145(11):5269-79. PubMed ID: 15284207
[TBL] [Abstract][Full Text] [Related]
37. Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.
Ghorbani-Aghbolaghi A; Darrow MA; Wang T
Autops Case Rep; 2017; 7(3):32-37. PubMed ID: 29043208
[TBL] [Abstract][Full Text] [Related]
38. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
[TBL] [Abstract][Full Text] [Related]
39. Challenges in the management of tumor-induced osteomalacia (TIO).
Brandi ML; Clunie GPR; Houillier P; Jan de Beur SM; Minisola S; Oheim R; Seefried L
Bone; 2021 Nov; 152():116064. PubMed ID: 34147708
[TBL] [Abstract][Full Text] [Related]
40. Hypophosphatemia related to a neuro-endocrine tumor of the pancreas: A case report.
Pickering ME; Bouvier D; Puravet A; Soubrier M; Sapin V; Oris C
Clin Biochem; 2022 Jun; 104():62-65. PubMed ID: 35337828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
